化合物ZL006
化合物ZL006 性质
| 沸点 | 530.4±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.617±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度≥5mg/mL（加热至60°C） |
| 酸度系数(pKa) | 3.40±0.10(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至棕褐色 |
| InChI | 1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21) |
| InChIKey | RTEYSQSXRFVKTJ-UHFFFAOYSA-N |
| SMILES | OC1=C(Cl)C=C(Cl)C=C1CNC(C=C2)=CC(O)=C2C(O)=O |
化合物ZL006 用途与合成方法
ZL006 presents little cytotoxicity, and a growth inhibition of BCECs is not found at low concentration of 0.001, 0.01, 0.1, 1 and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is significantly enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs. ZL006 does not inhibit the nNOS-PDZ/PSD-95-PDZ interaction, or perturb the nNOS β-finger.
Compared with P-LPs/ZL006 and free ZL006, T7-P-LPs/ZL006 exhibits a significant increase of drug accumulation in the brain tissue due to its better brain targeting delivery. Compared with free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 exhibit a significant decrease of drug accumulation in the liver and kidney.
化合物ZL006 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-100456 | 化合物ZL006 | 1181226-02-7 | 5mg | 420 |
| 2026-09-15 | HY-100456 | 化合物ZL006 | 1181226-02-7 | 10mM * 1mLin DMSO | 462 |
